98%
921
2 minutes
20
Introduction Professional awards and honors given by the medical societies help their members to boost their academic excellence and encourage leadership opportunities. The present study aimed to analyze the gender distribution of award recipients, identify any existing gender disparities, and assess factors influencing recognition in the field of ophthalmology. Methods This was an observational study with data extracted from the publicly available All India Ophthalmological Society (AIOS) website. Seventy-three years of data from the award recipients were reviewed. Individuals' gender was determined based on the first name and confirmed through internet searches of pronoun descriptors from professional websites. Key outcome measures were the gender distribution by year (1949-2022), category (achievement, scientific investigation/research, contribution to society/leadership, or lifetime achievement), and nomination type (self or society). Comparisons were made using Fisher's exact and chi-square tests when appropriate, with statistical significance set at a two-tailed P-value of <0.05. Results Of 452 award recipients across 31 AIOS award categories between 1949 and 2022, 323 recipients (71.5%) were men and 129 (28.5%) were women. Men received 96.7%, 78.6%, and 65.2% of awards in the contribution to society/leadership, achievement, and scientific investigation/research category, respectively, highlighting a significant underrepresentation of women in award distribution. Analysis of factors influencing gender distribution revealed that the award year, nomination type, and award category significantly impacted gender representation. Notably, fewer women were awarded before the start of the 21st century, and self-nominated candidates were predominantly skewed towards male recipients. Conclusion This study reveals significant gender disparities in award distribution within the Indian Ophthalmological Society. However, an increase in the proportion of female awardees over the years suggests a positive trend towards inclusivity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177209 | PMC |
http://dx.doi.org/10.7759/cureus.84438 | DOI Listing |
Prev Oncol Epidemiol
May 2025
Implenomics, Dover, DE, USA.
Introduction: We identified potential approaches to address barriers to colorectal cancer (CRC) screening in rural communities of award recipients from the Centers for Disease Control and Prevention's Colorectal Cancer Control Program (CRCCP).
Methods: Nine program managers and directors discussed approaches to address barriers to CRC screening. The programs served areas with rural communities and tribal reservations.
Plast Reconstr Surg
September 2025
Division of Plastic Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine.
Background: One of the goals of the Plastic Surgery Foundation (PSF) is to initiate a pathway by which researchers can develop national extramurally-funded grants. The present study investigates the effectiveness of seed PSF grants in aiding researchers to obtain grant funding through the National Institutes of Health (NIH).
Methods: The NIH RePORTER database was queried with the names of all American Society of Plastic Surgeons (ASPS) members.
Transfusion
September 2025
Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, Canada.
Background: There is limited high-quality evidence to guide plasma transfusion, and plasma transfusion practices remain variable.
Study Design And Methods: This is a retrospective cohort study that included adult medical and intensive care unit (ICU) inpatients (age ≥ 18 years) admitted to 23 hospitals in Canada between January 1, 2017, and December 31, 2022, when both whole blood derived (~290 mL) and apheresis plasma (~250 mL) were available for transfusion. Nine additional hospital sites with missing plasma data or coagulation testing were excluded.
J Infus Nurs
August 2025
Author Affiliations: PGY-1 Pharmacy Practice Resident (Dr Van), Infectious Diseases Clinical Pharmacy Specialist (Dr Lee), University of California, Irvine Medical Center; and School of Pharmacy and Pharmaceutical Sciences (Dr Johannesmeyer), University of California, Irvine.
Front Oncol
August 2025
Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, United States.
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [Lu]Lu-PSMA-617 and guide therapy decision-making.
View Article and Find Full Text PDF